OSMT Stock Overview
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary.
Osmotica Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.13|
|52 Week High||US$4.95|
|52 Week Low||US$0.98|
|1 Month Change||14.84%|
|3 Month Change||-41.75%|
|1 Year Change||-74.02%|
|3 Year Change||-86.22%|
|5 Year Change||n/a|
|Change since IPO||-86.13%|
Recent News & Updates
Osmotica: A Different Breed Of Cat
Having closed on the sale of its legacy business, Osmotica had UPNEEQ, arbaclofen ER, and little else. Despite having downsized, Osmotica is still incurring significant and growing ongoing expenses. Running UPNEEQ as a standalone business is challenging and may be doomed to failure. Before deciding on UPNEEQ's investment merits, consider its forthcoming launch into the ocular aesthetics market.
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|OSMT||US Pharmaceuticals||US Market|
Return vs Industry: OSMT underperformed the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: OSMT underperformed the US Market which returned 13.7% over the past year.
|OSMT Average Weekly Movement||11.2%|
|Pharmaceuticals Industry Average Movement||10.5%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: OSMT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: OSMT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company’s promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women’s health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.
Osmotica Pharmaceuticals Fundamentals Summary
|OSMT fundamental statistics|
Is OSMT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSMT income statement (TTM)|
|Cost of Revenue||US$75.22m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.27|
|Net Profit Margin||-63.62%|
How did OSMT perform over the long term?See historical performance and comparison
Is Osmotica Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OSMT ($1.13) is trading below our estimate of fair value ($54.13)
Significantly Below Fair Value: OSMT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OSMT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: OSMT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSMT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OSMT is good value based on its PB Ratio (1.7x) compared to the US Pharmaceuticals industry average (2.3x).
How is Osmotica Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSMT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: OSMT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OSMT's is expected to become profitable in the next 3 years.
Revenue vs Market: OSMT's revenue (35.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: OSMT's revenue (35.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OSMT's Return on Equity is forecast to be high in 3 years time
How has Osmotica Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSMT is currently unprofitable.
Growing Profit Margin: OSMT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSMT is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare OSMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSMT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: OSMT has a negative Return on Equity (-192.77%), as it is currently unprofitable.
How is Osmotica Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: OSMT's short term assets ($23.4M) do not cover its short term liabilities ($53.9M).
Long Term Liabilities: OSMT's short term assets ($23.4M) exceed its long term liabilities ($867.0K).
Debt to Equity History and Analysis
Debt Level: OSMT's net debt to equity ratio (39.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if OSMT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSMT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OSMT has less than a year of cash runway if free cash flow continues to grow at historical rates of 35% each year.
What is Osmotica Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSMT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSMT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian Markison (62 yo)
Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison has been an Operating Executive and Healthcare Industry Execu...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD3.83M) is above average for companies of similar size in the US market ($USD578.13K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
Experienced Management: OSMT's management team is seasoned and experienced (6 years average tenure).
Experienced Board: OSMT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OSMT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.1%.
Osmotica Pharmaceuticals plc's employee growth, exchange listings and data sources
- Name: Osmotica Pharmaceuticals plc
- Ticker: OSMT
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$94.118m
- Shares outstanding: 83.29m
- Website: https://www.osmotica.com
Number of Employees
- Osmotica Pharmaceuticals plc
- 400 Crossing Boulevard
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 23:31|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.